Medtronic is a medical technology company headquartered in Galway, Ireland. It serves healthcare systems, physicians, clinicians and patients in more than 150 countries. Its three reportable segments develop, manufacture, distribute and sell device-based medical therapies and services: Cardiovascular, Neuroscience, and Medical Surgical. The Cardiovascular portfolio includes products for heart rhythm disorders, heart failure, heart valve and aortic disease, and coronary and peripheral vascular conditions. Neuroscience offers surgical, spinal, neurovascular, ear, nose and throat, pelvic health, and neuromodulation therapies. Medical Surgical provides surgical and endoscopy products, robotic-assisted surgery technologies, patient monitoring and airway management products. Medtronic sells medical devices and therapies through direct sales representatives and third parties, including independent distributors and agents. Its Diabetes Business develops and sells insulin pumps, continuous glucose monitoring systems and related consumables, and is included among its other businesses.
TD Cowen reiterated a Buy rating and $110 price target for Medtronic (NYSE:MDT) after FDA clearance of its Hugo system for general surgery, expanding its U.S. market. The stock, currently at $102.88, has risen 37% in six months. Piper Sandler also upgraded MDT to Overweight, citing growth drivers. Medtronic announced a prospectus correction for its MiniMed exchange offer.
Piper Sandler upgraded Medtronic to Overweight from Neutral, raising its price target to $120 from $85, a 41.2% increase. The new target implies a 16.6% upside from the Nov 16 close of $102.88.
Medtronic (MDT) is scheduled to release Q2'26 earnings on November 24, with estimated revenue of $9.48B and EPS of $1.33. Results will be announced at 6:45 AM ET.
via TradingView
MDT sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 15 news stories mentioning MDT (Medtronic plc). Coverage has skewed bullish: 12 bullish, 3 neutral, and 0 bearish.
The analyst upgrade and higher target are likely to support near-term sentiment and attract incremental dip-buying, though it is not a company fundamental disclosure.
AlphAI scores every news story that mentions MDT with an AI model for sentiment and relevance, and aggregates insider trades from Medtronic plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
TD Cowen reiterated a Buy rating and $110 price target for Medtronic (NYSE:MDT) after FDA clearance of its Hugo system for general surgery, expanding its U.S. market. The stock, currently at $102.88, has risen 37% in six months. Piper Sandler also upgraded MDT to Overweight, citing growth drivers. Medtronic announced a prospectus correction for its MiniMed exchange offer.
Piper Sandler upgraded Medtronic to Overweight from Neutral, raising its price target to $120 from $85, a 41.2% increase. The new target implies a 16.6% upside from the Nov 16 close of $102.88.
Medtronic (MDT) is scheduled to release Q2'26 earnings on November 24, with estimated revenue of $9.48B and EPS of $1.33. Results will be announced at 6:45 AM ET.
Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.
Bridgewater Associates adjusted its US equity portfolio in Q3, increasing stakes in Nvidia, Broadcom, and memory chips like Qualcomm, Micron, and SanDisk, while reducing positions in Alphabet, Amazon, and industrial stocks. The hedge fund's total market value was about $23 billion as of Sept. 30, with Nvidia remaining the largest semiconductor holding at $614 million. Bridgewater also exited Union Pacific and Paccar, and added new positions in energy and healthcare.
Former Medtronic CEO Bill George suggests Nvidia (NVDA) should add experienced executives to its board to secure its future. The company is searching for a new CEO after Jensen Huang's ouster amid controversy. Colette Kress, CFO, is interim CEO ahead of earnings release.
Medtronic (NYSE: MDT) plans to acquire Contego Medical, a private medical device company specializing in carotid artery disease and peripheral thrombectomy treatments. The deal, valued at $380 million, includes Contego's FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter.
Johnson & Johnson (JNJ), Abbott Laboratories (ABT), and Medtronic (MDT) are highlighted for their long dividend growth streaks and steady demand in healthcare. JNJ, with a 64-year streak, aims for $100B revenue, yields 1.91%, and has a AAA credit rating. ABT, a Dividend Aristocrat, yields 2.28% and focuses on aging population growth. MDT offers the highest yield at 2.77% and the lowest forward multiple. All three cover payouts with adjusted earnings and free cash flow.
Cornerstone Robotics, a Hong Kong-based surgical robotics company, hosted its inaugural Surgical Futures Forum, gathering global healthcare leaders. Medtronic invested $700M in Cornerstone, partnering to distribute its Sentire(R) Surgical System globally. Speakers highlighted Hong Kong's push to become a medical device innovation hub and the potential of surgical robotics to improve patient access and outcomes.
Medtronic (MDT) has seen a 58.9% share price increase over three years. Analysts are evaluating if this growth is supported by the company's cash flow generation, which currently sits around $6.1b in free cash flow over the last twelve months. Positive clinical data and FDA labeling expansions may support future cash inflows. The DCF model suggests the stock is broadly in line with its intrinsic value at $101.80, but opinions on its valuation vary.